ACS Medicinal Chemistry Letters · 2019 · 45 citations · 17 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyLigand BindingLigand-based DesignNuclear ReceptorsPotency OptimizationProtein-ligand DockingReceptor-ligand InteractionsLigand Design For ReceptorsMolecular ReceptorsNuclear Receptor HeterodimersNuclear Receptor TargetingPhysicochemical PropertiesRetinoid ReceptorsRetinoid X ReceptorsStructure-based Ligand Design
As universal heterodimer partners of many nuclear receptors, the retinoid X receptors (RXRs) constitute key transcription factors. They regulate cell proliferation, differentiation, inflammation, and metabolic homeostasis and have recently been proposed as potential drug targets for neurodegenerative and inflammatory diseases. Owing to the hydrophobic nature of RXR ligand binding sites, available synthetic RXR ligands are lipophilic, and their structural diversity is limited. Here, we disclose the computer-assisted discovery of a novel RXR agonist chemotype and its systematic optimization toward potent RXR modulators. We have developed a nanomolar RXR agonist with high selectivity among nuclear receptors and superior physicochemical properties compared to classical rexinoids that appears suitable for in vivo applications and as lead for future RXR-targeting medicinal chemistry.
17
Retinoid X receptor gamma signaling accelerates CNS remyelination
Jeffrey K. Huang, Andrew A. Jarjour, Brahim Nait‐Oumesmar et al. · Nature Neuroscience · 2010 · 549 citations · Full text
Oliver Rau, Mario Wurglics, Alexander Paulke et al. · Planta Medica · 2006 · 223 citations